Przejdź do zawartości
Merck

ZMS1075

Sigma-Aldrich

Anti-SARS-CoV-1/2 NP Antibody, clone 1C7C7 ZooMAb® Mouse Monoclonal

enhanced validation
greener alternative

recombinant, expressed in HEK 293 cells

Synonim(y):

NC, Nucleocapsid protein, Protein N.

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych


About This Item

Kod UNSPSC:
12352203
NACRES:
NA.43

pochodzenie biologiczne

mouse (recombinant)

Poziom jakości

rekombinowane

expressed in HEK 293 cells

białko sprzężone

unconjugated

forma przeciwciała

purified antibody

rodzaj przeciwciała

primary antibodies

klon

1C7C7, recombinant monoclonal

linia produktu

ZooMAb® learn more

Postać

lyophilized

masa cząsteczkowa

calculated mol wt 45.63 kDa (SARS-CoV-2)
calculated mol wt 46.03 kDa (SARS-CoV)
observed mol wt ~46 kDa

reaktywność gatunkowa

SARS virus

opakowanie

antibody small pack of 25 μL

charakterystyka ekologicznej alternatywy

Waste Prevention
Designing Safer Chemicals
Design for Energy Efficiency
Learn more about the Principles of Green Chemistry.

rozszerzona walidacja

recombinant expression
Learn more about Antibody Enhanced Validation

sustainability

Greener Alternative Product

metody

affinity binding assay: suitable
flow cytometry: 1 μg/mL
immunocytochemistry: suitable
western blot: 1 μg/mL

izotyp

IgG2aκ

numer dostępu UniProt

kategoria ekologicznej alternatywy

Warunki transportu

ambient

temp. przechowywania

2-8°C

docelowa modyfikacja potranslacyjna

unmodified

informacje o genach

SARS coronavirus ... N(43740575)
SARS virus ... N(1489678)

Opis ogólny

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.
ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.

Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.

Learn more about ZooMAb here.

Specyficzność

Clone 1C7C7 is a ZooMAb mouse recombinant antibody that specifically detects SARS-CoV-1/2 NP.

Immunogen

His-tagged full-length recombinant Nucleoprotein from SARS-CoV virus.

Zastosowanie

Anti-SARS-CoV-1/2 NP, clone 1C7C7 ZooMAb, Cat. No. ZMS1075, is a Mouse monoclonal antibody that detects nucleoprotein from SARS-CoV-1/2 and is tested for use in Affinity Binding Assay, Flow Cytometry, Immunocytochemistry, and Western Blotting.
Flow Cytometry Analysis: 1 mg /ml from a representative lot detected SARS-CoV-1/2 NP in Transfected 293expi cells (Courtesy of Dr Thomas Moran, Center for Therapeutic Antibody Development).

Immunocytochemistry Analysis: 1 μg/mL from a representative lot detected SARS-CoV-1/2 NP in Vero E6 cells infected with SARs-CoV-2 (Courtesy of Dr Ana Fernandez-Sesma Laboratory, Icahn School of Medicine at Mount Sinai (ISMMS), New York).

Western Blotting Analysis: A 1:5,000 dilution of this antibody detected SARS-CoV-1/2 NP in lysate from A549 cells infected with SARS-CoV-2 (Courtesy of Jeff Johnson Laboratory, Icahn School of Medicine at Mount Sinai (ISMMS).

Affinity Binding Assay: This antibody bound recombinant nucleoprotein from SARS-CoV-1/2 with a KD of 4.4 x 10-7 in an affinity binding assay.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Opis wartości docelowych

Nucleoprotein (UniProt: P59595/P0DTC9; also known as Nucleocapsid protein, NC, Protein N) is encoded by the N gene (Gene ID: 1489678) in Human SARS coronavirus. The SARS-CoV-2 (COVID-19 causing virus) is a positive-strand RNA virus that causes severe respiratory syndrome in human. The mature SARS-CoV-2 contains 4 structural proteins: Envelope (E), Membrane (M), Nucleocapsid (N), and the Spike protein (S). Nucleoprotein of SARS-CoV and SARS-CoV-2 is a homooligomeric protein that packages the positive strand viral genome RNA into helical ribonucleocapsid and plays a role in virion assembly through its interactions with the viral genome and membrane protein M. It plays an important role in enhancing the efficiency of subgenomic viral RNA transcription as well as viral replication. The RNA binding region of SARS-CoV and SARS-CoV-2 is localized to amino acids 42-187 and 41-186, respectively. Lack of cysteine is one of the common features in nucleoprotein from different coronaviruses. The complete N protein of SARS-CoV and COV-2 is a highly basic with positive net charges and high pI (10.11). Its N-terminal region is more basic with positive charge, while the C-terminal region is acidic with negative charge. The middle region of nucleoprotein displays relatively higher hydrophobicity and the two termini display greater hydrophilicity. Nucleoprotein can undergo phosphorylation at multiple serines by GSK-3, CKII, Akt, CDKs, and Polo-like kinases. Some of these phosphorylation events are essential for RNA binding, oligomerization and localization to nucleoli. Phosphorylation is also required for recruitment of host RNA helicase DDX1 (DEAD-Box Helicase 1) that facilitates template readthrough and enables longer subgenomic mRNA synthesis. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.

Postać fizyczna

Purified mouse monoclonal antibody IgG2a in buffer containing PBS, 5% Trehalose without preservatives

Rekonstytucja

300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Przechowywanie i stabilność

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Informacje prawne

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Oświadczenie o zrzeczeniu się odpowiedzialności

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Data presented is the available current product information and provided as-is. These products have not been tested or verified in any additional applications, sample types, including any clinical use. Experimental conditions must be empirically derived by the user. Our Antibody Guarantee only covers tested applications stated herein and conditions presented in our product information and is not extended to publications.

Not finding the right product?  

Try our Narzędzie selektora produktów.

Kod klasy składowania

11 - Combustible Solids

Klasa zagrożenia wodnego (WGK)

WGK 1

Temperatura zapłonu (°F)

Not applicable

Temperatura zapłonu (°C)

Not applicable


Certyfikaty analizy (CoA)

Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Caleb D Swaim et al.
iScience, 24(10), 103213-103213 (2021-10-12)
The emergence of SARS-CoV-2 has led to a global health crisis that, in addition to vaccines and immunomodulatory therapies, calls for the identification of antiviral therapeutics. The papain-like protease (PLpro) activity of nsp3 is an attractive drug target as it
Varun Dwivedi et al.
GeroScience, 46(3), 2901-2913 (2024-02-23)
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still an ongoing global health crisis. Clinical data indicate that the case fatality rate (CFR) is age dependent, with a higher CFR percentage in the elderly
Jeonghwan Kim et al.
Advanced science (Weinheim, Baden-Wurttemberg, Germany), 9(35), e2202556-e2202556 (2022-10-11)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can cause lethal pulmonary damage in humans. It contains spike proteins on its envelope that bind to human angiotensin-converting enzyme 2 (hACE2) expressed on airway cells, enabling entry of the virus, and causing
Astha Thakkar et al.
eLife, 12 (2023-03-29)
Cancer patients show increased morbidity with COVID-19 and need effective immunization strategies. Many healthcare regulatory agencies recommend administering 'booster' doses of COVID-19 vaccines beyond the standard two-dose series, for this group of patients. Therefore, studying the efficacy of these additional
J Andrew Duty et al.
Med (New York, N.Y.), 3(10), 705-721 (2022-09-01)
The continual emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern, in particular the newly emerged Omicron (B.1.1.529) variant and its BA.X lineages, has rendered ineffective a number of previously FDA emergency use authorized SARS-CoV-2 neutralizing antibody

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej